Related Experiment Video

Updated: Jul 15, 2025

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.5K

Physiological effects of ivabradine in heart failure and beyond

Audra N Iness1, Keyur M Shah2, Rakesh C Kukreja3

  • 1Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.

Molecular and Cellular Biochemistry
|September 28, 2023
PubMed

Insights

Ivabradine selectively inhibits the heart rate funny current. While not yet proven to reduce mortality in heart failure, its other effects may benefit hyperadrenergic states and COVID-19 complications.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Ivabradine targets the sinoatrial node's funny current, regulating heart rate.
  • Its use in heart failure is explored for benefits like reduced myocardial oxygen demand and improved diastolic filling.
  • Definitive mortality benefits in heart failure remain unproven.

Purpose of the Study:

  • Review clinical trials on ivabradine's efficacy in heart failure.
  • Explore ivabradine's pleiotropic effects beyond heart rate reduction.
  • Investigate potential applications in hyperadrenergic states and COVID-19 complications.

Main Methods:

  • Review of key clinical trials.
  • Analysis of pharmacological effects and clinical outcomes.
  • Exploration of potential therapeutic applications based on existing data.

Main Results:

  • Ivabradine reduces heart rate by inhibiting the funny current.
  • Clinical trials show potential benefits in heart failure but lack definitive mortality reduction.
  • Ivabradine influences the renin-angiotensin-aldosterone system, sympathetic activation, and endothelial function.

Conclusions:

  • Ivabradine is a heart rate-lowering agent with potential benefits in heart failure.
  • Its pleiotropic effects warrant further investigation for broader clinical applications.
  • Potential uses include managing hyperadrenergic conditions and mitigating COVID-19-related issues.

Keywords:
Funny currentHeart failureIschemiaIvabradineSinoatrial node

More Related Videos

Impact of Intracardiac Neurons on Cardiac Electrophysiology and Arrhythmogenesis in an Ex Vivo Langendorff System06:40

Impact of Intracardiac Neurons on Cardiac Electrophysiology and Arrhythmogenesis in an Ex Vivo Langendorff System

Published on: May 22, 2018

10.7K
Rodent Working Heart Model for the Study of Myocardial Performance and Oxygen Consumption12:43

Rodent Working Heart Model for the Study of Myocardial Performance and Oxygen Consumption

Published on: August 16, 2016

20.3K

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
357
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
611
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
454
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
12
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
14